Author(s): Bttiger Y, Brattstrm C, Tydn G, Swe J, Groth CG
Abstract Share this page
Abstract AIMS: To evaluate the relationship between tacrolimus whole blood concentrations and side-effects and rejections in 14 renal transplant recipients. METHODS: Tacrolimus was measured by MEIA in whole blood in samples collected repeatedly during the first year after transplantation. Retrospectively, tacrolimus trough concentrations on the days with adverse events (n=172) or rejection (n=28) were related to the total distribution of the concentration values (n=656). RESULTS: Side-effects (one or more) were noted in connection with 76\% of tacrolimus concentrations above 30 ng ml-1, with 41\% of concentrations within the interval of 20-30 ng ml-1, with 26\% of the concentrations within the interval of 10-20 ng ml-1 and with only 5.3\% on the concentrations lower than 10 ng ml-1. No relation to the tacrolimus concentration was seen for rejection episodes. CONCLUSIONS: We conclude that therapeutic drug monitoring may be helpful in the management of tacrolimus therapy and that tacrolimus whole blood trough concentrations (MEIA) should preferably be kept below 20 ng ml-1 to avoid side-effects, such as nephro-and neurotoxicity and infections. The lower limit of the therapeutic range has yet to be defined.
This article was published in Br J Clin Pharmacol
and referenced in Journal of Pharmacogenomics & Pharmacoproteomics